Trellus Health Strike New Partnership Agreement & Licensed Clinical Team
Well the ‘commercialisation ball’ is well & truly rolling for , who IPO’d in May raising £28.5m at 40p to commercialise its unique resilience/AI led telemedicine platform.
Indeed unrivalled expertise on all things related to ‘chronic disease management’ (eg Crohn’s & Colitis) - alongside its proprietary science-enabled methodologies.
Means that its complete 'holistic' approach provides substantial patient quality of life, efficiency & cost saving benefits - whilst equally being applicable across other debilitating illnesses.
Today on top of its August ‘Demonstration’ contract with Mount Sinai Health System, announced its 1st ‘white-label’ agreement with Connected Health Medicine.
A New York based healthcare provider that will offer multidisciplinary patient care for chronic medical conditions to its clients. Here will supply its GRITTTM resilience system, the telehealth platform & associated scientific/technical expertise.
In my view this is a perfect ‘soft-launch’ deal that should thoroughly ‘road-test’ all the moving parts. Before later offering similar ‘highly scalable’ services to much larger healthcare providers, insurers, hospitals &/or medical organisations across not only the US (initially), but also later the world.
Exciting times ahead & very well done Marla Dubinsky, Laurie Keefer, PhD, Monique Fayad & the wider team.
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.